Cover Image
市場調查報告書

肺支氣管發育不良 : 開發平台分析

Bronchopulmonary Dysplasia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213096
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
肺支氣管發育不良 : 開發平台分析 Bronchopulmonary Dysplasia - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 64 Pages
簡介

肺支氣管發育不良是慢性疾病之一,是出生時接受人工呼吸器治療之早產兒中惡化的疾病之一。症狀有呼吸急促,心搏過速,更進一步的呼吸困難,皮膚發青色等。原因有先天性心臟病,嚴重呼吸感染疾病/肺感染疾病等。

本報告提供肺支氣管發育不良的治療藥開發情形相關調查,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

肺支氣管發育不良概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肺支氣管發育不良:企業開發中的治療藥

肺支氣管發育不良:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

肺支氣管發育不良:企業開發中的產品

肺支氣管發育不良的治療藥開發企業

  • Airway Therapeutics, Inc.
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Mallinckrodt Plc
  • MediPost Co., Ltd.
  • Syntrix Biosystems, Inc.
  • Therabron Therapeutics, Inc.

肺支氣管發育不良:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AT-100
  • budesonide
  • CG-100
  • Drugs for Bronchopulmonary Dysplasia
  • gefitinib
  • nitric oxide
  • Pneumostem
  • R-190
  • R-801
  • R-901
  • R-908
  • SX-576
  • Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders

肺支氣管發育不良:最近的開發平台趨勢

肺支氣管發育不良:暫停中的計劃

肺支氣管發育不良:開發中止的產品

肺支氣管發育不良:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8378IDB

Summary

Global Markets Direct's, 'Bronchopulmonary Dysplasia - Pipeline Review, H2 2016', provides an overview of the Bronchopulmonary Dysplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia
  • The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects
  • The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bronchopulmonary Dysplasia Overview
  • Therapeutics Development
    • Pipeline Products for Bronchopulmonary Dysplasia - Overview
  • Bronchopulmonary Dysplasia - Therapeutics under Development by Companies
  • Bronchopulmonary Dysplasia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bronchopulmonary Dysplasia - Products under Development by Companies
  • Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
    • Airway Therapeutics LLC
    • Chiesi Farmaceutici SpA
    • Insmed Incorporated
    • MediPost Co., Ltd.
    • Meridigen Biotech Co., Ltd.
    • Syntrix Biosystems, Inc.
    • Therabron Therapeutics, Inc.
  • Bronchopulmonary Dysplasia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mecasermin rinfabate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pneumostem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-190 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-908 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-911 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapies for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bronchopulmonary Dysplasia - Dormant Projects
  • Bronchopulmonary Dysplasia - Discontinued Products
  • Bronchopulmonary Dysplasia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2016: Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
      • May 25, 2016: Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants
      • May 03, 2016: MEDIPOST receives US Patent for 'PNEUMOSTEM' for Treating Lung Disease
      • Apr 28, 2016: Therabron Therapeutics Receives FDA Fast Track Designation for rhCC10 for the Prevention of Chronic Lung Disease Related to Premature Birth
      • Apr 13, 2016: Therabron Therapeutics Receives Notice of Allowance for New Patent Supporting the Recombinant CC10 Technology Platform
      • Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate
      • Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial
      • Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform
      • Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program
      • May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia
      • Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung
      • Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial
      • Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage'
      • Feb 06, 2014: Stem cells to treat lung disease in preterm infants
      • Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bronchopulmonary Dysplasia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics LLC, H2 2016
  • Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H2 2016
  • Bronchopulmonary Dysplasia - Pipeline by Insmed Incorporated, H2 2016
  • Bronchopulmonary Dysplasia - Pipeline by MediPost Co., Ltd., H2 2016
  • Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co., Ltd., H2 2016
  • Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems, Inc., H2 2016
  • Bronchopulmonary Dysplasia - Pipeline by Therabron Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bronchopulmonary Dysplasia - Dormant Projects, H2 2016
  • Bronchopulmonary Dysplasia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bronchopulmonary Dysplasia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top